Navigation Links
Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
Date:6/27/2012

WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

"This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition. We are happy to see this latest evidence that the FDA is joining the effort to treat obesity seriously," said Dr. Patrick O'Neil, President of The Obesity Society.

Dr. O'Neil continued, "At the same time, it is important to understand that this medication will not work overnight or by itself. Lifestyle changes and support from qualified professionals are still necessary. This is an obesity medication, not a diet pill."

The OCC supports the FDA's continued dedication to excellence in ensuring the safety and effectiveness of new obesity treatments. With more than 93 million Americans affected by obesity, it is imperative to continue this proactive momentum and forward-thinking approach with all safe and effective therapies for the disease.

"We are very pleased with the FDA's decision. These are serious medications for a serious issue. In order for us to fight this epidemic, the right patients must receive the right treatment from a qualified physician in combination with a diet and exercise program," said Joe Nadglowski, Obesity Action Coalition (OAC) President and CEO.

About the Obesity Care Continuum (OCC):

With a combined membership of more than 125,000 healthcare professionals and patient advocates, the Obesity Care Continuum (OCC) is dedicated to promoting access to, and coverage of, the continuum of care surrounding the treatment of overweight and obesity. The OCC also challenges weight bias and stigma oriented policies – whenever and wherever they occur. The OCC is a coalition of the Obesity Action Coalition (OAC), the Obesity Society (TOS), and the American Society for Metabolic and Bariatric Surgery (ASMBS).


'/>"/>
SOURCE Obesity Care Continuum
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
2. LTCLINK-Tank Competition Announced To Introduce Your Emerging Product to the Aging Care Continuum
3. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
6. CHPA Applauds Alabamas Adoption Of HB 363
7. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
10. ERT Announces Stockholder Approval of Merger
11. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):